Fortis Life Sciences
Home chevron_right Products chevron_right Lateral Flow Reagents chevron_right Infectious Disease

The High Cost of Poor
LFA Antibodies

Weak lateral flow assay antibodies, antigens, and colloidal gold conjugates can propagate failures in infectious disease testing from development to clinical use creating cascading scientific, manufacturing, commercial and clinical consequences..

Whether you're struggling with consistency, specificity, or manufacturability, we can help.

×
Gloved hand applying a drop of liquid with a pipette onto a test strip.

The Impact is Broad,
And Avoidable

Scientific Consequences

Blue checkmark icon.
Variable performance across pathogen variants, serotypes, sample matrices, and testing conditions
Delays from failed verification and repeated bridging work
Increased cost from wasted materials and repeated testing
Lost development cycles due to inconsistent LFA analytical behavior

Commercial Consequences

Delayed launch timelines
Reduced competitiveness
Lost revenue opportunities

Manufacturing Consequences

Production delays caused by unstable lots
Wasted membranes, conjugates, and finished tests
Increased cost from troubleshooting and repeated QC
Disrupted supply commitments

Clinical Consequences

Reduced sensitivity and specificity
Transmission risks from false negatives
Blue checkmark icon
Disrupted treatment decisions from false positives

Trust Your Reagents. Clinical Decisions Depend On Them.

You need rapid test antibodies, antigens, and conjugates that hold performance as pathogens evolve and manufacturing conditions change. Stable LFA reagents protect development timelines, reduce failed lots, and support clean verification and validation.

Arista Biologicals, a Fortis Life Sciences company, delivers reagents that maintain signal strength, control cross-reactivity, and demonstrate batch-to-batch reproducibility through validation, creating a smoother and more reliable path to market.

Download The Brochure >
Arista Biologicals Infectious Disease Antibodies and Antigens brochure cover

Supporting Reliable LFA Performance Across High-Priority Pathogens

3D render of the West Nile Virus

NEW!

West Nile Virus

Well-characterized monoclonal antibodies against the West Nile virus envelope protein bind strongly to viral surface antigens from multiple lineages, enabling sensitive detection of intact virus while reducing cross‑reactivity with other flaviviruses.
3D render of the Dengue Virus (DENV 1–4)

Dengue Virus (DENV 1–4)

Core NS1 antibodies evaluated for broad serotype coverage and minimal flavivirus cross-reactivity.
3D render of the Helicobacter pylori spiral-shaped, gram‑negative bacterium

Helicobacter Pylori

High-purity LFA reagents that maintain performance in complex gastric matrices.
3D image of the Hepatitis B Virus (HBV)

Hepatitis B Virus (HBV)

High-affinity antibody detection in both vaccinated and unvaccinated populations, tested for stable performance in lateral flow formats.
3D render of the Hepatitis C Virus (HCV)

Hepatitis C Virus (HCV)

Pan-genotypic LFA reagents that maintain sensitivity across global HCV diversity.
Microscope-style image of clustered yellow spherical particles against a blue background.

Human Immunodeficiency Virus (HIV)

Antigen targets selected for conserved epitope recognition and tested for consistent performance in lateral flow formats.
3D illustration of golden spherical cell-like particles floating against a red background.

Influenza A and Influenza B

Antibodies targeting conserved nucleoprotein regions for reliable lateral flow assay performance across seasonal shifts.
Red blood cells with malaria Plasmodium parasites inside

Plasmodium Species (Malaria)

Reagents selected for reliable detection across species and for stable performance in low parasitemia settings.
3D render of the SARS-CoV-2 (COVID-19) virus.

SARS-CoV-2 (COVID-19) Reagents

Antibodies and antigens selected for consistent detection across emerging variants and stable signals in lateral flow systems
3D render of Treponema Pallidum (Syphilis) spirochete bacterium

Treponema Pallidum

Antigens are prepared to preserve structural integrity and support consistent detection across disease stages.
Talk With An Expert

Trust our high-quality lateral flow assay antibodies, antigens, and conjugates to support reliable performance and ensure dependable results for the clinical decisions that rely on your assays.